Takeda Pharmaceutical Co Ltd ADR (TAK)

16.60
-0.01(-0.06%)
After Hours
16.60
0.00(0.00%)
- Real-time Data
  • Volume:
    1,424,584
  • Bid/Ask:
    16.50/16.60
  • Day's Range:
    16.60 - 16.72

TAK Overview

Prev. Close
16.6
Day's Range
16.6 - 16.72
Revenue
-
Open
16.72
52 wk Range
15.3 - 19.97
EPS
-
Volume
1,424,584
Market Cap
52.25B
Dividend (Yield)
1.22 (8.16%)
Average Vol. (3m)
2,960,408
P/E Ratio
-
Beta
-
1-Year Change
-7.16%
Shares Outstanding
-
Next Earnings Date
May 11, 2021
What is your sentiment on Takeda Pharmaceutical Co Ltd ADR?
or
Market is currently closed. Voting is open during market hours.

Takeda Pharmaceutical Co Ltd ADR News

Takeda Pharmaceutical Co Ltd ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Takeda Pharmaceutical Co Ltd ADR Company Profile

Takeda Pharmaceutical Co Ltd ADR Company Profile

Industry
Major Drugs
Employees
47495
Market
Japan

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Read More
  • Dividend yield shows as 1.22 (8.16%), I believe this is incorrect information as both NasdaqCom and Finviz + Yahoo Finance show a Yield of  4.13% and 4.84% respectively  - I don't understand why so much incongruence between sources, is anyone able to explain? Thanks!
    0
    • could be related to the way it is calculated (taking into account the last available price vs average of last 12months)
      0
  • ARK bought 1.2 Million yesterday
    0
    • this is going up..volume doubled in the last two days
      0
      • What's going on guys?
        0
        • It's going to 21$ soon
          0
          • oh~
            0
            • Dengue and Covid have similar incubation times and some shared symptoms. we'll need testing to differentiate.
              0
              • Phase III Four Complex Dengue trial response appears robust, and successful thus far. The FDA vax is proven not successful (dangerous) for populations 15 yrs and younger. Takeda's solution covers all age ranges in two doses.
                0
                • bullish
                  0
                  • any news ? please TAKEDA is it worths to entry ?
                    0
                    • hello Mr. Davaa do you think Takeda is for short investment ? what do you advise please ?
                      0
                      • Davaa Battsogtthank you so  much I think next week I will entry . If I need any opinion can I ask you again ? thank you so much for your very kind advises and opinions appreciated so much.
                        0
                      • SS SS Thank you. I'm not strong on stock market but I progress by little step.
                        0
                      • Davaa Battsogtok lets focus in Takeda . if you have any other advise or opinion please let me know your opinion will be highly appreciated so much . Szilike.
                        0
                    • Japanese mentality doesn't lie never.
                      0
                      • hello
                        0
                        • Takeda leads the run of COV19 Vax.Soon will be 100+
                          0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.